Medina-Aymerich Lorena, Ngo Ngoc Betty, Gonzalez Daniel, Hornik Chi D, Al-Uzri Amira, Greenberg Rachel G, Anderson Sarah G, Payne Elizabeth H, Turdalieva Sitora, Balevic Stephen J
Duke Clinical Research Institute, Durham, North Carolina, USA.
Division of Clinical Pharmacology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
J Clin Pharmacol. 2025 May 16. doi: 10.1002/jcph.70044.
Alfentanil is an opioid analgesic and anesthetic agent used in surgical procedures. Despite its widespread use in children, the U.S. Food and Drug Administration label lacks specific dosing recommendations for those under 12 years. A population pharmacokinetic analysis was performed using NONMEM (v7.5) to characterize alfentanil's disposition in children. The study included 58 plasma concentrations from 42 patients who received intravenous alfentanil as part of usual care. Median age was 7.57 years (range: 0.33-17.80) and median dosing was 12.5 mcg/kg (range: 4-43). A one-compartment model with first-order elimination best described alfentanil's pharmacokinetics. Among body size measures, total body weight (WT) significantly influenced clearance (CL [L/h]) = 7.42 × (WT/70)) and volume of distribution (V [L]) = 12.6 × (WT/70)1). Inter-individual variability decreased after the inclusion of WT, coefficients of variation were reduced from 104% to 58% and from 169% to 83%, for CL and V, respectively. The final model facilitated simulations to achieve target efficacious analgesic and anesthetic concentrations. For analgesia, an initial 10 mcg/kg bolus (for the first hour) followed by an 8 mcg/kg/h infusion (starting at 1 h) achieved the efficacious targeted concentrations (10-100 ng/mL). For procedures that typically require minimal or moderate sedation, a 25 mcg/kg bolus followed by a 20 mcg/kg/h infusion (starting at 5 min) achieved the targeted concentrations (50-200 ng/mL, depending on the procedure). These regimens should be prospectively evaluated to ensure their safety and confirm their efficacy. Overall, this study provides valuable insights into pharmacokinetics and dosing of alfentanil in children.
阿芬太尼是一种用于外科手术的阿片类镇痛药和麻醉剂。尽管它在儿童中广泛使用,但美国食品药品监督管理局的标签缺乏针对12岁以下儿童的具体给药建议。使用NONMEM(v7.5)进行了群体药代动力学分析,以描述阿芬太尼在儿童体内的处置情况。该研究纳入了42例接受静脉注射阿芬太尼作为常规治疗一部分的患者的58个血浆浓度数据。中位年龄为7.57岁(范围:0.33 - 17.80岁),中位给药剂量为12.5 mcg/kg(范围:4 - 43)。具有一级消除的一室模型最能描述阿芬太尼的药代动力学。在身体大小指标中,总体重(WT)对清除率(CL [L/h])= 7.42×(WT/70))和分布容积(V [L])= 12.6×(WT/70)1)有显著影响。纳入WT后个体间变异性降低,CL和V的变异系数分别从104%降至58%和从169%降至83%。最终模型有助于进行模拟以达到目标有效镇痛和麻醉浓度。对于镇痛,初始10 mcg/kg静脉推注(第1小时),随后8 mcg/kg/h输注(从1小时开始)可达到有效目标浓度(10 - 100 ng/mL)。对于通常需要最小或中度镇静的手术,25 mcg/kg静脉推注,随后20 mcg/kg/h输注(从5分钟开始)可达到目标浓度(50 - 200 ng/mL,取决于手术)。这些给药方案应进行前瞻性评估,以确保其安全性并确认其有效性。总体而言,本研究为阿芬太尼在儿童中的药代动力学和给药提供了有价值的见解。